Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Cardiol. Sep 26, 2014; 6(9): 939-958
Published online Sep 26, 2014. doi: 10.4330/wjc.v6.i9.939
Table 2 miRNAs as potential diagnostic and prognostic biomarkers in myocardial infarction
miRNAs as potential biomarkerRole of biomarkerExpression in body fluidSpecies and body fluidRef.
let-7bPotential diagnostic valueUpPlasma; human[72]
let-7fDifferentiating TTC and MIDownPlasma; human[79]
miR-1Detection of AMI and APUpExosome, serum; human and mouse[59]
Correlation with MI sizeUpSerum; rat and human[60]
Differentiating AMI and APUpSerum; human[61]
Differentiating AMI and other cardiovascular diseasesUpPlasma; rat and human[67]
Similar time course to cTnI and the same trend to cTnI concentrationUpPlasma and tissue; human and mouse[68,70]
Differentiating AMI and non-AMIUpPlasma; human[69]
AMI biomarkers, not superior to cTnTUpPlasma; human[71]
Associated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)UpPlasma; human[76]
No association with 30 d mortality post-MI and diagnosis of HFUpPlasma; human[81]
Biomarker for AMI, correlated with renal eliminationUpPlasma, urine; human, pig[85]
Detected in urineUpUrine; rat[86]
miR-16Differentiating TTC and MIDownPlasma; human[79]
Higher risk of impaired LV contractilityUpPlasma; human[83]
miR-21Associated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)NdPlasma; human[76]
Differentiating NSTEMI and CHFUpPlasma; human[78]
Time-dependent changes 2-90 d post-MIDown, upPlasma; human[80]
miR-26aDifferentiating TTC and MIDownPlasma; human[79]
miR-27aHigh risk of impaired LV contractilityUpPlasma; human[83]
miR-29aTime-dependent changes 2-90 d post MIUpPlasma; human[80]
miR-29bAssociated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)NdPlasma; human[76]
miR-30aPotential diagnostic valueUpPlasma; human[72]
miR-30cCorrelation with MI sizeUpWhole blood; human[64]
miR-34aPrognostic: correlated with LV end diastolic dimensionUpExosomes, serum; human[62]
miR-101Higher risk of impaired LV contractilityDownPlasma; human[83]
miR-126The same trend to cTnI expressionDownPlasma; human[70]
Positive association to the risk for MINdPlasma; human[84]
miR-133aDetection of AMI, AP: biomarker for cardiomyocyte deathUpExosome, serum; human and mouse[59]
AMI biomarker, correlation to cTnIUpPlasma and whole blood; human[66]
Differentiating AMI and other cardiovascular diseasesUpPlasma; rat and human[67]
Similar time-course to cTnIUpPlasma and tissue; human and mouse[68]
AMI biomarkers, not superior to cTnTUpPlasma; human[71]
Differentiating AMI and AP, positive correlation to severity of coronary stenosisUpPlasma; human[75]
Associated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)UpPlasma; human[76]
Differentiating TCC and MIUpPlasma; human[79]
Biomarker for AMI, correlated with renal eliminationUpPlasma, urine; human, pig[85]
miR-133bSimilar time-course to cTnIUpPlasma and tissue; human and mouse[68]
miR-134Differentiating AMI and APUpSerum; human[61]
miR-145Correlation with MI sizeUpWhole blood; human[64]
miR-146aAssociated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)NdPlasma; human[76]
miR-150Associated with LV remodelingDownPlasma; human[82]
Higher risk of impaired LV contractilityDownPlasma; human[83]
miR-155Prognostic for cardiac death within 1 yr after MIUpSerum; human[63]
Associated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)NdPlasma; human[76]
miR-181c*Novel mirna dysregulated during MINdWhole blood; human[65]
miR-186Differentiating AMI and APUpSerum; human[61]
miR-192Prognostic for development of ischemic HFUpExosomes, serum; human[62]
miR-194Prognostic: correlated with LV end diastolic dimensionUpExosomes, serum; human[62]
miR-195Potential diagnostic valueUpPlasma; human[72]
miR-197Negative association to the risk for MINdPlasma; human[84]
miR-208Differentiating AMI and APUp in AP compared to AMISerum; human[61]
Differentiating AMI and other cardiovascular diseasesUpPlasma; rat and human[67]
Time-dependent changes 2-90 d post MIUpPlasma; human[80]
Detected in urineUpUrine; rat[86]
miR-208bAMI biomarkers, correlation to cTnT but not superior to cTnTUpPlasma; human[71,76]
Differentiating STEMI and NSTEMIHigher in STEMIPlasma; human[73]
Associated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)UpPlasma; human[76]
Higher risk for 30 d mortality post-MI and HFUpPlasma; human[81]
Biomarker for AMI, correlated with troponinUpPlasma, urine; human, pig[85]
miR-223Differentiating AMI and APUpSerum; human[61]
Associated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)DownPlasma; human[76]
Negative association to the risk for MINdPlasma; human[84]
miR-328AMI biomarker, correlation to cTnIUpPlasma and whole blood; human[66]
miR-380*Prognostic for cardiac death within 1 yr after MIUpSerum; human[63]
miR-423-5pBefore PCI compared to afterUpPlasma; human[77]
miR-499Differentiating AMI and APUp in AP compared to AMISerum; human[61]
Differentiating AMI and other cardiovascular diseasesUpPlasma; rat and human[67]
Similar time course to cTnIUpPlasma and tissue; human and mouse[68]
AMI biomarkers, correlation to cTnT but not superior to cTnTUpPlasma; human[71,76]
Differentiating STEMI and NSTEMIHigher in STEMIPlasma; human[73]
Differentiating MI, CHF and unstable APUpPlasma; human[74]
Associated with various degree of cardiovascular damage (AMI, viral myocarditis, diastolic dysfunction, acute HF)Up and also in acute HFPlasma; human[76]
Differentiating NSTEMI and CHFUpPlasma; human[78]
Higher risk for 30 d mortality post MI and HFUpPlasma; human[81]
Biomarker for AMI, correlated with renal eliminationUpPlasma, urine; human, pig[85]
miR-1915Novel miRNA dysregulated during MINdWhole blood; human[65]
11 miRNAsPrognosis after MIUp and downSerum; human[63]
20 miRNAsPredicting AMI (96% specificity; 90% sensitivity; 93% accuracy)Up and downWhole blood; human[64]
A subset of miRNAsDysregulated during AMI courseNdWhole blood; human[65]
34 miRNAsAMI biomarkers20 up, 14 downPlasma and tissue; human and mouse[68]
19 candidate miRNAsPrediction for risk of MINdPlasma; human[84]